Truscreen downgrades sales expectations
Biotech minnow posts half-year loss, declines to comment on receivables.
Biotech minnow Truscreen [NZX: TRU], which is seeking to revive cervical cancer testing technology developed by defunct Australian company Polartechnics, has downgraded full-year sales expectations after posting a first half loss.
Revenue for the NZAX listed Truscreen was $305,882 for the six
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Tim Hunter
Mon, 14 Dec 2015
Mon, 14 Dec 2015
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Truscreen downgrades sales expectations
54337